


Paricalcitol-d₆

| | | | |
|---------------------------|---|-------|---------|
| Cat. No.: | HY-76585 | | |
| CAS No.: | 2070009-67-3 | | |
| Molecular Formula: | C ₂₇ H ₃₈ D ₆ O ₃ | | |
| Molecular Weight: | 422.67 | | |
| Target: | VD/VDR | | |
| Pathway: | Vitamin D Related/Nuclear Receptor | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (236.59 mM; Need ultrasonic)
 DMSO : 100 mg/mL (236.59 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent \ Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|----------------|-----------|------------|------------|
| | Concentration | | | |
| | 1 mM | 2.3659 mL | 11.8296 mL | 23.6591 mL |
| | 5 mM | 0.4732 mL | 2.3659 mL | 4.7318 mL |
| | 10 mM | 0.2366 mL | 1.1830 mL | 2.3659 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Paricalcitol-d₆ is the deuterium labeled Paricalcitol. Paricalcitol is a agent used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure[1].

REFERENCES

- [1]. Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. *Am J Physiol Renal Physiol.* 2012 Aug 8.
- [2]. Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, Odabasi D. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. *Br J Radiol.* 2012 Aug;85(1016):1038-43.
- [3]. Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Silljé HH, Ruifrok WP, de Boer RA. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. *J Steroid Biochem Mol Biol.* 2012 Jul 16;132(3-5):282-289.

[4]. Blanco-García R, et al. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease. *Nefrologia*. 2012 May 14;32(3):401-2. doi: 10.3265/Nefrologia.pre2012.Feb.11378.

[5]. Piao SG, Song JC, Lim SW, Chung BH, Choi BS, Yang CW. Protective effect of paricalcitol on cyclosporine-induced renal injury in rats. *Transplant Proc*. 2012 Apr;44(3):642-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA